Targeted nanotherapy with everolimus reduces inflammation and fibrosis in scleroderma-related interstitial lung disease developed by PSGL-1 deficient mice.
González-Sánchez E, Muñoz-Callejas A, Gómez-Román J, San Antonio E, Marengo A, Tsapis N, Bohne-Japiassu K, González-Tajuelo R, Pereda S, García-Pérez J, Cavagna L, González-Gay MÁ, Vicente-Rabaneda EF, Meloni F, Fattal E, Castañeda S, Urzainqui A.
González-Sánchez E, et al. Among authors: gomez roman j.
Br J Pharmacol. 2022 Sep;179(18):4534-4548. doi: 10.1111/bph.15898. Epub 2022 Jul 13.
Br J Pharmacol. 2022.
PMID: 35726496
Free article.